Anatara Lifesciences Ltd FY2026 Financial Report
Key points
- Net loss after tax for the year attributable to members decreased by 52% to $(933,230)
- No dividends were paid or declared for the financial year
- Anti-Obesity Project showed promising pre-clinical results but placed on hold
- Successful capital raising of A$1.2m in November 2025
- GaRP-IBS trial showed statistically significant improvements in IBS symptoms
Full summary
Anatara Lifesciences Ltd reported a net loss after tax for the year attributable to members of $(933,230), a 52% decrease from the previous year. No dividends were paid or declared for the financial year. The Anti-Obesity Project showed promising pre-clinical results but was placed on hold. The company completed a successful capital raising of A$1.2 million in November 2025. The GaRP-IBS trial showed statistically significant improvements in IBS symptoms, including pain severity, pain frequency, and abdominal distension. The company's cash position improved significantly, with cash at the end of the year at $0.471 million compared to $0.101 million in the previous year.
Outlook
Anatara Lifesciences Ltd remains committed to advancing the Anti-Obesity Project and evaluating additional opportunities within the healthcare sector. The company is assessing potential transactions and strategic directions to address significant unmet medical needs.
Summary generated by a large language model. Please interpret with care.